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Abstract
Background: The purpose of the study was to outline the genomic and epidemiological characteristics of COVID-19 in
South Asian countries as well as the diagnosis, treatments, and prevention approaches undertaken by these countries to
tackle the COVID-19 pandemic.
Methods: We searched electronic databases such as Google Scholar, PubMed, and Scopus as well as various national
and international COVID-19 websites, WHO databases, and electronic media. 63 articles were included from databases
and 34 articles from various other sources.
Results: Scientists observed genomic variations including common mutations in ORF1ab, ORF1a, ORF3a, and S genes,
while several unique mutations exist in most isolates from these countries. Demographic analysis showed that the
majority of infected individuals were male and younger adults (20e40 years). India had the highest number of deaths
and incidents while Afghanistan had the highest fatality rate (4.37%). Various molecular assays including rRT-PCR,
antigen and antibody-based assays have been developed and pre-existing treatments have been used to combat the
pandemic. Although every country tried to implement imperative preventive measures along with vaccination drives,
many of them still face grave repercussions due to impoverished health systems, underdeveloped infrastructures, and
improvident government policies.
Conclusion: To our knowledge, this is the ﬁrst review appraising various features of SARS-CoV-2 and COVID-19 that
persists in South Asia and strategies undertaken by the countries to tackle the disease. This review will facilitate timely
interventions for future novel outbreaks in the region.
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1. Introduction

C

OVID-19 began as an unprecedented outbreak
of pneumonia that originated in China and
was declared a pandemic later. The virus was later
named Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) [1,2]. The World Health
Organization (WHO) announced Coronavirus disease-2019 (COVID-19) as the name of the disease
and identiﬁed it as a threat to global public health
on 30 January 2020 [2]. It is the seventh of the
already identiﬁed respiratory syndrome diseasecausing human coronaviruses. The epidemic
causing SARS-CoV in China and the MERS-CoV in
the Middle East are the two other coronaviruses that
previously endangered human lives [3,4]. The
genome of SARS-CoV-2 is composed of RNA, and
thus evolves through mutations more often than the
DNA virus. Hence, it demonstrated continuous and
unique mutations which made it more difﬁcult to
suppress [5]. At ﬁrst, mutations in the spike protein
(e.g. D614G, Y453F) were considered most
dangerous because the virus infects the host cell
with the spike protein [6]. However, since then,
numerous distinct mutations have been found in
various regions of its genome. As of now, four variants have been identiﬁed: the Alpha variant (B.1.1.7
from the UK), the Beta variant (B.1.351 from South
Africa), the Gamma variant (P1 from Brazil), and the
Delta variant (B.1.617.2 from India) [7].
According to the WHO, more than 188.6 million
infected cases and over four million deaths have been
reported with a fatality rate of 2.15% as of 16 July 2021.
The USA is the most affected country to date with 33.6
million conﬁrmed cases, constituting almost 18% of
all cases, and 603,170 deaths as of 16 July 2021 [8]. The
South Asian countries (SAC) have also been devastated by this highly infectious disease. In particular,
densely populated countries like India and
Bangladesh are more susceptible to the virus. As a
result, these countries face grave challenges in tackling the virus. As of 16 July 2021, a total of 34,300,319
people have been infected and 472,726 have lost their
lives in the region [9]. Despite various precautionary
measures, the “Second Wave of COVID-19’ has
struck South Asia massively. Additionally, rapid and
unpredictable mutations made it difﬁcult to tackle
the virus, despite vaccination drives.
To the best of our knowledge, this is the ﬁrst review article that aims to discuss genomic alterations
and epidemiological patterns of COVID-19 in South
Asia. Besides diagnostic methods used, treatment
and preventive tactics for COVID-19 taken by the
countries in South Asia were also our issues of
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interest. Appraising these topics is a matter of urgent concern. Hopefully, countries that have been
affected severely can adopt the policies of the
countries that have successfully controlled the
spread of COVID-19 and avoided the worst ramiﬁcations of COVID-19.

2. Methods
A comprehensive search was conducted following
the methods of a previous study [10]. We searched
electronic databases such as PubMed, Scopus and
Google Scholar for published articles using the
combination of the following terms including the
name of the countries of South Asia, “COVID-19,”
“coronavirus,’’ “Genomes,” “Diagnostic systems,”
“Epidemiology,’’ “Treatments,’’ “Prevention strategies,” We identiﬁed a total of 677 articles by initial
searching. After screening and assessment, 63 articles were considered. To make the scope broader, a
quality assessment was not performed. Other
necessary articles were retrieved from WHO databases and national and international websites
dedicated to COVID-19 information and electronic
media because of the unavailability of information
from database articles. Finally, information was
discussed and reported in this study. Fig. 1 illustrates the search strategy and method applied.
2.1. Ethical approval and consent for publication
Not applicable.

3. Results
3.1. Genomic features
Genetic variations analysis of SARS-CoV-2 suggests
that like all RNA viruses, it contains numerous mutation frequencies. India sequenced the maximum
number of SARS-CoV-2 genomes (973) among SAC,
followed by Bangladesh (415), Pakistan (260), Nepal
(11), and Sri Lanka (4) as of 1 June 2021 [11].
Afghanistan, Bhutan, and the Maldives have not reported any genome sequencing yet.
A study on 184 SARS-CoV-2 genomes from
Bangladesh found 634 mutations that include 274
non-synonymous amino acid (AA) substitutions in
22 different proteins. AA mutations were prevalent
at 48 different positions of the papain-like protease
(nsp3). Moreover, nine unique mutations were
observed in comparison with global strains in the
spike proteins [12]. Another investigation of 371
genomes identiﬁed 4604 mutations, including 2862
missense, 1192 synonymous, and 25 INDEL
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Fig. 1. Flow diagram of the search strategy.

(insertion and deletion) mutations. Phylogenetic
analysis implicated that the virus originated from
Europe and the GR clade was most prevalent.
Another signiﬁcant ﬁnding in these SARS-CoV-2
genomes was 34 unique alterations of AA in various
proteins [13].
A study of 566 Indian genomes found 3384 unique
point mutations, including substitution (933) and
INDEL mutations (2451). Additionally, 64 single
nucleotide polymorphisms (SNP) were found. Of
them, 57 were present in six coding regions, and 7
were present in 50 -UTR and 30 -UTR [14]. Another
comparative study found that all the identiﬁed
clades of SARS-CoV-2 were present in the study
population and 19B had the highest occurrence. In
the viral spike protein, D614G mutation was predominant [15]. Additionally, the whole-genome
sequence phylogeny and the patient's itinerary
implicated the origin of Indian strains from the
Middle East and Europe [16].
The genomes from Nepalese isolates were more
than 99.99% identical to two previously sequenced
SARS-CoV-2 genomes (MN988668 and NC_045512)
from Wuhan, China. Moreover, ﬁve mutations
including both silent and non-synonymous mutations were identiﬁed in ORF1a, ORF1b, ORF8b, and
nucleocapsid based on the reference sequence
EPI_ISL_405839 [17].
Full and partial genome sequencing of eight Pakistani isolates showed that the earlier prevailing viral
strains were clustered with strains from Saudi Arabia,
India, the United States, Australia, and China. Of the
eight strains, ﬁve were GH clade that contains mutations in the S protein and Ns3 gene, three were L,

two were S and one was I clade. Furthermore, the
ORF1ab variant L3606F was observed in one GH and
one L strain, which implicated evolutionary transitions of the virus [18]. Four whole-genome sequences
of a study identiﬁed 31 variants, including deletion in
ORF1ab, ORF1a, and N genes that have functional
roles in replication and translation of SARS-CoV-2.
Mutations in N & ORF1a proteins showed alterations
at the AA level [19].
Phylogenetic analysis of four Sri Lankan isolates
found clusters of mostly European strains. SNP
analysis revealed that the genome sequences had
different variations compared to the reference
genome, such as variations in the six nucleotide, ﬁve
nucleotide, and four nucleotide positions. Moreover,
AA variants were found in the ORF1ab protein, S
protein, ORF3a gene, M gene, and N protein of all
four whole-genome strains [20].
3.2. Epidemiological characteristics
India, Pakistan, and Bangladesh are the three
countries with the highest occurrences and deaths
in South Asia. Nearly 91% of the infected individuals were from India. Although Afghanistan
had a comparatively lower incidence, testing rates
were also the lowest in this country. So, it might be
possible that many cases in Afghanistan were not
identiﬁed. Moreover, Afghanistan had the highest
fatality rate (4.37%), followed by Pakistan and
Bangladesh. Bhutan had the lowest number of
infected patients and deaths; cumulatively, 1309 individuals were infected, while only one died in the
country. Meanwhile, 33,102,065 of the patients from

Table 1. Case distribution and vaccination of COVID-19 in South Asian countries.
Country

Total conﬁrmed
cases

Total deaths

Mortality
rate

Total Recovered

Recovery
rate

Number of vaccine
doses administered

Afghanistan
Bangladesh
Bhutan
India
Maldives
Nepal
Pakistan
Sri Lanka

139,051
1,084,922
2,398
31,064,908
75,736
664,576
986,668
282,060

6,072
17,465
2
413,091
216
9,506
22,760
3,614

4.37
1.60
0.08
1.33
0.29
1.43
2.30
1.29

86,219
911,643
2,038
30,227,792
72,930
628,243
918,329
254,871

62.0
84.0
85.0
97.3
96.3
94.5
93.1
90.4

1,024,168
10,554,425
486,126
394,978,565
561,748
3,589,051
21,660,650
5,720,328

these countries recovered from the disease by 16
July 2021. In Table 1, the highest recovery rate was
observed in India (97.3%), while Afghanistan had a
relatively low recovery rate (62%).
Due to the rapid spread to a large population, it
was difﬁcult to maintain a complete database that
included every individual. Existing demographic
data analysis showed that variations existed among
the different age groups of COVID-19 cases in SAC
excluded Bhutan (Demographics data was not
available and unspeciﬁed cases are not indicated)
(Fig. 2). The majority of the infected patients were
young adults aged between 20 and 40 years, except
in Sri Lanka, where the majority of the patients were
aged 40e49 years [21e27]. There is no scientiﬁc
evidence yet explaining the higher infection rate
among the younger population. However, it is easily
perceivable that younger people may be more likely
to avoid preventive practices, such as using face

16.5
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5.0

9.3

7.8

12.2
13.6

masks, maintaining social distance, and quarantining after potential exposure.
Regarding gender distribution, males had a
higher infection rate (Fig. 3) than females. Previous
literature showed that females are genetically and
immunologically more resistant to SARS-CoV-2
infection. The X chromosome has elevated immune
regulating genes, and females possess double X
chromosomes [28]. The virus utilizes angiotensinconverting enzyme 2 (ACE-2) as both receptor and
the route of infection. Studies found that Asian
males have elevated expression of ACE-2 receptors
compared to females. Also, female ovaries had
much lower levels of ACE-2 than testes [29,30].
Moreover, men were more vulnerable to cytokine
storm syndrome occurring in response to SARSCoV-2 attack. This occurs because men have a
higher likelihood of producing cytokines resulting
in cytokine storms [27]. Several social and cultural
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Fig. 2. Age distribution of COVID-19 infected patients in South Asian countries.
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Fig. 3. Sex distribution of COVID-19 infected patients in South Asian countries.

factors are also deemed to be responsible. For
example, smoking, tobacco use, and alcohol consumption are more prevalent in men [30]. Moreover,
females were more aware of the hygiene practices to
prevent COVID-19 and adopted precautionary
measures more early than men [31].
3.3. Diagnostics approaches
Since the onset of the pandemic, many countries
had been trying to overcome it through various
courses of action. Of these, diagnostic measures
have received prime attention. Different molecular
tests including the real-time reverse transcriptasepolymerase chain reaction (rRT-PCR) and serological tests such as the rapid diagnostic test (RDT),
Enzyme-Linked Immunosorbent Assay (ELISA),
neutralization assay, and chemiluminescent immunoassay are being used [32]. The rRT-PCR of nasopharyngeal swabs or oropharyngeal swabs is
considered the ‘gold standard.’ Various protocols
have been uploaded to WHO technical guidance
[33]. A majority of the SAC focused on increasing
the number of rRT-PCR labs with well-equipped
amenities, as well as producing cost-effective kits
along with various molecular and serological assays.
The detection of this viral RNA is highly speciﬁc but
it is less sensitive in some cases which can take a
relatively long time and may produce false-negative
results. Yet, rRT-PCR is still the most widely used
and most accurate method for the detection of

SARS-CoV-2 [34]. Table 2 lists the diagnostic
methods that were approved for use in SAC.
India had the highest number of diagnostic labs
(2750), including 933 TrueNat and 132 CBNAAT labs
as of 16 July 2021, albeit it still struggling to meet the
demand [35]. Most of the countries were very far
from testing and screening all the suspected cases.
Afghanistan was conducting only 9,064 tests per
million population, which is the lowest rate in South
Asia, followed by Bangladesh (29,214 tests/1,000,000
population) and Pakistan (46,812 tests/1,000,000
population) as of 6 April 2021 (Fig. 4) [36].
3.4. Treatment and interventions
In Afghanistan, a controversial drug containing
addictive substances including morphine and codeine became a topic of considerable discussion as a
potential treatment for COVID-19among the general public. Although the government and health
experts warned against this unproven drug, people
burst with excitement for the medication [51]. The
country is facing grave repercussions due to inadequate and substandard treatment facilities. The
government also faced difﬁculties meeting the
required number of healthcare professionals and
protective equipment. There was a preponderance
of health care workers who had to purchase PPE
even though their salary was very low. A large
number of hospital-acquired infections were caused
by the virus [52].

Table 2. COVID-19 diagnostic methods in South Asian countries.
Country name

Screening Method

Synopsis

References

Afghanistan

rRT-PCR

Sample: Nasopharyngeal swab, oropharyngeal swab, sputum and/
or bronchoalveolar lavage.
Sample: Nasopharyngeal swab, oropharyngeal swab, sputum,
and/or bronchoalveolar lavage.
Sample: Saliva.
Detects E gene and N2 region of the N gene of SARS-CoV-2
Result: within 50 minutes.
Sample: Saliva and swab
Result: within 15 minutes
Reliability: 97.7% sensitivity and 96% speciﬁcity.
Sample: Nasopharyngeal swab, oropharyngeal swab, sputum,
and/or bronchoalveolar lavage.
Sample: Blood
Result: 30 minutes
Reliability: 70% sensitivity and 90% speciﬁcity.
Sample: Nasopharyngeal swab, oropharyngeal swab, sputum,
and/or bronchoalveolar lavage.
2-step process,
Step 1: E gene screening assay Step 2: RdRp gene conﬁrmatory
assay
Result: 30e60 minutes
Reliability 100%.
2-step process,
Step 1: E gene screening assay
Step 2: SARS-CoV-2 speciﬁc N2 region of the N gene.
Result: 30e60 minutes
Reliability: 100%.
Sample: Nasopharyngeal swab.
Result: within 30 minutes.
Reliability: 50.6%e84% sensitivity and 99.3e100% speciﬁcity.
Sample: Blood serum or plasma.
Reliability: 92.4% sensitivity and 97.9% speciﬁcity.
Sample: Nasal or throat swab.
Result: within 1hour
Reliability: 100% sensitivity and 97% speciﬁcity.
Sample: Nasopharyngeal swab, oropharyngeal swab, sputum,
and/or bronchoalveolar lavage.
Sample: Swab sample.
Identiﬁcation of E gene and N2 region of the N gene of SARS-CoV2
Reliability: 97% sensitivity, 98.5% speciﬁcity.

[37]

rRT-PCR
Bangladesh

GeneXpert Covid-19 Test

Rapid Dot Blot

rRT-PCR
Bhutan

RDT

rRT- PCR
TrueNAT

CBNAAT

RAT

India

COVID ELISA (IgG ELISA test)
Feluda-CRISPR Test

rRT-PCR
Maldives

GeneXpert cartridges

RAT (BinaxNOW COVID-19 Ag
Card)
rRT-PCR
Nepal

RDT
rRT-PCR

Pakistan

Antigen detection Rapid Diagnostic Tests (Ag-RDT)

Sri Lanka

rRT-PCR

Sample: Nasopharyngeal swab, oropharyngeal swab, sputum,
and/or bronchoalveolar lavage.
Sample: Blood.
Reliability: 50% sensitivity, 99.5% speciﬁcity.
Sample: Nasopharyngeal swab, oropharyngeal swab, sputum and/
or bronchoalveolar lavage.
Sample: nasopharyngeal swab (NSP) and saliva
52% sensitivities for NSP-RDT
21% sensitivities for Saliva-RDT.
Sample: Nasopharyngeal swab, oropharyngeal swab, sputum,
and/or bronchoalveolar lavage.

In Bangladesh, physicians prescribed dexamethasone and antiviral drugs such as remdesivir or
favipiravir for critical patients [53,54]. A local pharmaceutical company introduced the world's ﬁrst
generic remdesivir [55]. Convalescent plasma therapy (CP) had a beneﬁcial impact on patients in
Bangladesh, especially in critical cases when plasma

[37]
[38,39]

[40]

[37]
[41]

[37]
[42,43]

[42,43]

[44]

[45]
[46]

[37]
[47]

[48]
[37]
[49]
[37]
[50]

[37]

therapy was the only option. The government
established a plasma network “Shohojoddha’’ to
expedite the availability [40].
The government of Bhutan provided free testing
amenities, which resulted in timely diagnosis and
treatment. Bhutan was praised by the WHO for its
prompt intervention. Patients having mild
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Fig. 4. COVID-19 tests per million population in South Asian countries.

symptoms with risk factors of pneumonia and other
symptoms were treated with hydroxychloroquine
with or without Lopinavir/Ritonavir [56]. Additional
therapies such as low molecular weight heparin,
steroids, and antibiotics were also being used based
on disease severity [57].
India, one of the most affected countries, is facing
a critical situation and is looking for effective treatment methods. Hydroxychloroquine was recommended for mild cases, whereas a combination of
the drug and azithromycin was prescribed for severe patients [58]. The central government authorized the use of two antiviral drugs, remdesivir, and
favipiravir but there has always been a debate
among the medical experts about their competency
in treating COVID-19 patients [59]. They approved
an anti-CD6 monoclonal antibody, itolizumab, for
moderate and severe patients [60]. CP therapy or
immune plasma therapy emerged as a hope for
critical patients. The Indian Council of Medical
Research commenced clinical trials to evaluate its
potential use and side effects, albeit the therapy was
already being used. This treatment served as a
short-term solution to reduce the fatality rate [61].
The Maldives published COVID-19 Guidelines
that recommended empirical antibiotics along with
oseltamivir based on clinical diagnosis [62]. Their
health system depends largely on non-native medical professionals, constituting 66% of doctors and
44% of nurses of total healthcare providers [63]. Also
being a country with many islands, decentralization
of the health facilities was quite difﬁcult.

Health experts in Nepal recommended antipyretics for mild patients. Antiviral drugs remdesivir
and favipiravir were prescribed for severe cases,
whereas chloroquine or hydroxychloroquine were
discouraged [64]. Ayurveda and traditional medicines have been approved as a management option
in the country because these proved to be immune
boosters. However, more evidence is needed
regarding its efﬁcacy [65]. They categorized
COVID-19 dedicated hospitals into three levels:
Level-1 for mild patients, Level-2 for moderate
patients, and Level-3 for critical patients who
needed specialized treatment, such as ventilators
or ICU [66].
In Pakistan, dexamethasone was being used to
treat critical COVID-19 in patients. The WHO
addressed it as a “lifesaving breakthrough” because
it showed a decreased fatality rate among critical
COVID-19 patients [67]. Another immune-suppressive drug, actemra, was used for critical SARSCoV-2 patients. The interleukin-6 (IL-6) inhibitor
was prescribed to patients with an abnormal level of
IL-6 leading to respiratory distress [68].
The Sri Lankan Guidelines on COVID-19 recommended antipyretics for mild patients [69]. Sri
Lanka is a country that promotes Ayurvedic and
herbal medicine to ﬁght COVID-19. Herbal therapy
has been introduced under government supervision. An immunizing drink named “Suwadharani
Immunizing Drink” and a powder named “Sadanga
Panaya” have been developed for individuals
infected with SARS-CoV-2 [70,71].

3.5. Preventive schemes
Amid the restoration process in war-torn
Afghanistan, the Afghan government tried to take
containment measures, including decreasing border
entry activity and arranging quarantine services for
infected people [72]. They announced a budget of
around 8 billion Afghanis for COVID-19-related
expenditures, including 1.9 billion Afghanis as an
immediate health necessity to mitigate the economic
blows [73]. The government and the United Nations
(UN) have developed schemes for mass vaccination
programs with vaccines free of cost through the
COVAX Advanced Market Commitment facility and
received the ﬁrst shipment of Covishield on 8 March
2021 [74].
In Bangladesh, after conﬁrming their ﬁrst three
cases, the government declared general holidays
and ordered a countrywide lockdown. They opened
telemedicine services and promulgated an obligatory quarantine of foreign returnees [75]. The
country was divided into three zones according to
the disease prevalence and implemented lockdown
measures accordingly [76]. Furthermore, the government provided 19 stimulus packages worth over
12.13 billion USD to support various sectors in
combating COVID-19 [40]. On 7 February 2021, a
nationwide vaccination began with the administration of 2 million doses of the Covishield vaccine
from India. Moreover, the government will receive
12.79 million doses of the Oxford University-AstraZeneca vaccine through the COVAX initiative
[77,78]. Bangladesh is also attempting to develop a
vaccine named “Bongovax.” It is being developed by
a local pharmaceutical ﬁrm, Globe Biotech, and
waiting for approval to conduct clinical trials [79].
Bhutan put great emphasis on preventing community transmission and initiated early measures,
such as an immediate national lockdown and contact tracing. They encouraged people to get testing
with free tests and to quarantine after exposure [80].
The government worked closely with the WHO to
provide the latest technical guidelines and strategies, which have facilitated the timely response to
tackle COVID-19 in the country [81].
After detecting its ﬁrst case, the government of
India minimized mobility by declaring the “Janata
Curfew,” which strictly maintained lockdown and
social distancing throughout the country [82]. They
set up 2 million retail shops called “Suraksha
Stores” to ensure everyday commodities to citizens
while maintaining safety practices [83]. A response
team was appointed to locate all possible contacts
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and demarcate the containment and safe zone according to the prevalence of infection [82]. Also, they
launched mobile apps such as “Aarogya Setu” and
“My Gov Corona Helpdesk” to disseminate information and ensure contact tracing [84]. The government granted several relief packages worth
about INR 29.7 trillion; INR 12.71 trillion were
monetary incentives and INR 17.16 trillion were
allocated to accelerate the economy and reduce the
repercussions of COVID-19 [85]. Recently, the
country has launched the world's biggest vaccination program by approving two vaccines: the Oxford/AstraZeneca vaccine, locally known as
Covishield, and India-based Bharat Biotech's Covaxin [79].
The Maldives was divided into six zones to
monitor the zones individually for engagement,
preparedness, and response. Remote resorts were
turned into quarantine centers [86]. In addition to
these, the government has developed schemes
including establishing effective patient ﬂow, utilizing web-based digital health tools, and ﬁnancing the
healthcare workforce to reduce the ramiﬁcations of
COVID-19 [87]. An economic relief package of 67.1
million USD was allocated to assist households and
businesses [88].
Nepal has taken timely interventions such as
limiting regular mobility, accelerating testing, as well
as implementing social distancing and contact
tracing. COVID-19ededicated hospitals were
equipped with increased amenities [89,90]. The federal government, in coordination with local and
provincial governments, has put in a great effort to
ensure the necessary logistical support and to raise
public awareness [89]. The country received 1 million
doses of the Covishield vaccine from India and inaugurated its vaccination drive on 27 January 2021
[77].
Following the detection of its ﬁrst positive case,
the Pakistani government activated the Emergency
Operation Centre that conducted training on surveillance and strengthened the existing healthcare
facilities. International ﬂights were suspended and
borders were shut. Educational institutions, shopping malls, and public gatherings were closed
down. Pakistan adopted “smart lockdown strategies” instead of a countrywide lockdown by recognizing high-risk areas and hotspots [91]. The
government budgeted an incentive package of 8
billion USD to assist businesses and the emergency
response and to provide relief to residents [92]. They
granted authorization for two vaccines: the OxfordAstraZeneca vaccine and the Sinopharm vaccine
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from China. Pakistan received 1,238,400 doses of
AstraZeneca's vaccines through COVAX on 8 May
2021 [93].
Sri Lanka introduced a range of preventive measures including travel restrictions, isolation of villages, and closure of airports to inbound passengers
[94,95]. All the SARS-CoV-2 positive patients were
treated (regardless of the severity of the disease) in
the state COVID-19 dedicated hospitals. The hospitals were facilitated with ICUs and ventilators for
critically ill patients. The country launched its
vaccination program on 29 January 2021 with the
administration of the Covishield vaccine. Over
118,767 health workers got vaccinated as of 31
January 2021 [96].
Vaccination is considered the only means of preventing the disease. All the South Asian countries
have started vaccination drives. India appeared to
be in the top position regarding access to vaccine
doses. However, only 5.7% of India's population was
fully vaccinated, whereas the Maldives has vaccinated over 65% of its population as of 16 July 2021
(Table 1) [35].

4. Discussion
Genome analysis of SARS-CoV-2 suggests that
despite some similarities, numerous distinct mutations were observed in genomes of various isolates
from the SAC. The most frequent mutations were
mostly insertions and/or deletions. Mutations in
ORF1ab, ORF1a, and ORF3 were predominant.
Moreover, SNPs were common, albeit alterations in
the levels of the amino acid signiﬁcantly vary in the
genomes. These unique and novel mutations have
made the virus more infectious than any other
coronaviruses. As a consequence, a preponderance
of the population is being infected despite taking
precautionary measures. The sudden appearance of
the delta variant (B.1.617.2), which originated from
India, has led to surging infection rates in neighboring countries. All the SAC except Pakistan has
recorded their highest number of COVID-19 cases
after the delta variant spread to these countries. It
was obvious that delta was more infectious than
previous variants [97,98]. Therefore, early and rapid
genome sequence-based surveillance and laboratory studies are needed to facilitate a “one-size-ﬁtsall” vaccine development strategy against the virus.
A majority of the countries in this region have had
difﬁculties tackling this disease due to underresourced healthcare facilities and a shortage of
healthcare professionals. They cannot meet the
recommended standards of 10 physicians and 44.5
health care professionals (doctors, nurses, and

midwives) per 10,000 people [99,100]. For example,
according to the World Health Statistics,
Afghanistan which has only 2.8 physicians per
10,000 people and 4.5 nurses and midwives per
10,000 people was greatly striving to attain the
required number of professionals. Bangladesh,
Bhutan, and India have a shortage of the required
number of health care professionals as well. Despite
having the requisite number of doctors, the
Maldives, Pakistan, and Sri Lanka lack the cumulative required number of health professionals
(Table 3) [101]. Many of them are not well-trained
enough to handle an infectious disease outbreak.
This situation has signiﬁcantly impacted the overall
management system and is reﬂected by the high
number of COVID-19 patients in several countries.
Afghanistan, Bangladesh, and India are facing
serious repercussions of COVID-19. It is very challenging for war-ravaged Afghanistan to provide
necessary amenities for its health care system, let
alone develop a surveillance system for a pandemic.
The country depends on foreign assistance and on
various international organizations such as the
WHO and the United Nations collaborating with the
government to continuously provide aid for health
and the economy. There have not been enough resources to restore health infrastructure and services
after the war's havoc. This situation has made it
quite impossible for Afghanistan to effectively
combat the pandemic, which is reﬂected by its high
fatality rate and low recovery rate. Bangladesh, one
of the most densely populated countries in South
Asia, could not impose strict mobility restrictions
because nearly one-ﬁfth of the population lives
below the poverty line [102]. Therefore, a relaxed
lockdown strategy was adopted, which has resulted
in several COVID-19 waves. In addition to these,
Bangladesh is highly dependent on foreign export
and import and could not prohibit transboundary
movements [103]. Moreover, the newly emerged
delta variant contributed to the rise of COVID-19
cases in the country. The Indian government's
improvident policies of relaxed movement
Table 3. The density of healthcare providers per 10,000 population in
South Asian countries.
Country

Physicians

Nurses and midwives

Afghanistan
Bangladesh
Bhutan
India
Maldives
Nepal
Pakistan
Sri Lanka

2.8
6.4
4.6
9.3
17.1
8.1
11.2
11.5

4.5
3.9
18.3
23.9
64.3
33.0
4.8
22.6

restrictions have been criticized by health experts.
They allowed people to celebrate festivals, such as
‘Holi’ and the ‘Kumbh Mela,’ where thousands of
individuals gathered without maintaining social
distance and preventive practices. A famous cricket
tournament was held with spectators crowded in a
closed environment. Moreover, a large number of
political supporters attended election rallies
[104,105]. All of these imprudent actions, along with
the highly infectious delta variant, contributed
signiﬁcantly to the surge in the infection rate in the
country.
Only proper testing, tracing, and treatment can
minimize the loss due to this virus. Still, a scarcity of
testing and treatment amenities exists in most of the
SAC. The need for digital health strategies has been
visible more than ever. All the countries have
prioritized their digital health care including
providing telemedicine and developing apps dedicated to COVID-19-related information. Vaccination has been started in most countries. Yet
controversy and distrust persist because of early
vaccine discovery. Covaxin from India has been
granted emergency use authorization. Authorities
of the SAC are working with various national and
international collaborators to ensure the distribution of vaccines. The UN, the Global Alliance for
Vaccines and Immunization (GAVI), and the WHO
are trying to ensure vaccines are distributed in the
lower and lower-middle-income countries through
COVAX facilities. Policymakers and public health
experts play signiﬁcant roles in popularizing rapid
and mass vaccination programs in the region.
Vaccines against the virus are the only hope to
combat this novel disease. Still, rapid and unpredictable mutation and transmission have made it
very difﬁcult to combat the pandemic. Hence, preventive measures and disease surveillance are key
strategies to tackle this pandemic. Smart and
balanced lockdown policies that sustain both
economy and health should be adopted. International and regional cooperation among the neighboring countries is mandatory to combat the
pandemic. Policymakers, government ofﬁcials, and
experts in various ﬁelds should come forward to
work hand in hand to establish sophisticated
response operations for future outbreaks.

5. Conclusion
COVID-19 is a matter of global concern. It has
challenged every sector, from health to economy
and society. The under-resourced South Asian
countries have faced the devastating effects of
COVID-19. They have utilized national and regional
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cooperation to mitigate its consequences. But the
shortage of healthcare facilities, impoverished public health infrastructures, and imprudent decisions
of policymakers have made it quite tough to handle
the outbreak. Also, because of the novel characteristics of the virus, it has been difﬁcult to implement
any systematic strategies to suppress it. This
pandemic has created an opportunity to rethink the
public health infrastructures of every country. If
utilized properly, it will be possible to develop
strategies to prevent future zoonotic outbreaks in
this region.
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